Hair loss drug showdown: tofacitinib vs methotrexate in new trial
NCT ID NCT07406204
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two oral medications—tofacitinib and methotrexate—for treating severe alopecia areata, an autoimmune condition causing hair loss. 78 adults aged 18-60 with severe scalp or total body hair loss will take one of the drugs for 12 weeks. The main goal is to see which medicine leads to more hair regrowth, measured by a standard hair loss score.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tofacitinib and methotrexate
- What this could lead to
- If successful, this could show that tofacitinib is a more effective option than methotrexate for regrowing hair in severe alopecia areata.
- What could go wrong
- This is a small, early-stage trial with only 78 participants and a short 12-week treatment period. Results may not apply to everyone, and both drugs have side effects like infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill help teens regrow hair lost to alopecia?
- Can allergy and glaucoma drugs regrow hair when delivered by microneedling?
- Can a daily pill bring back hair in severe alopecia?
- Can Real-World data unlock better skin disease care?
- Can a daily pill regrow hair in alopecia areata? a trial seeks answers
- Blood test may reveal hidden clues to hair loss severity